Aier Eye Hospital Investment Quality Review (300015.SZ)

Data timestamp: 2026-07-17 22:04 UTC
Quality score: 80/100 Valuation position: price/base fair value 1.38 Final signal: WATCHLIST

Core View

The report keeps the stock on the watchlist because business quality is not matched by sufficient valuation safety. The current price is 8.68CNY; conservative and base fair values are 3.6243/6.3029CNY. The source report’s conclusion is preserved: this is not a buy upgrade unless the margin of safety improves and the evidence base remains intact.

Quality is scored at 80/100. The positive evidence is the five-year financial baseline, latest free cash flow, and balance-sheet bridge. The main limits are valuation, incomplete segment-margin disclosure, and the need to keep validating shareholder returns, incentives, related-party exposure, accounting quality, and financial-asset composition from official filings.

Business Breakdown

The source report uses the consolidated business line as the operating base. Revenue moved from CNY 15.0bn to CNY 22.4bn, with a five-year change of 10.5%. Latest segment margin or segment profit is not disclosed, so no undisclosed segment margin is inferred.

The value driver is the multi-year revenue trend and the latest-year FCF. The business breakdown feeds the quality score and FCF multiple range; it is not treated as a separate valuation shortcut. Management outlook is used only when disclosed through annual reports, exchange filings, or company IR materials.

Business Quality

The scorecard totals 80/100: business model 7/10, moat 13/20, cash flow 20/20, capital return 11/15, balance sheet 8/10, growth quality 10/10, and management/accounting 11.4/15.

Cash-flow evidence: FCF/ 1.14OCF/ 1.69. Capital-return evidence: 5ROE 18.3%ROIC 14.7%. Balance-sheet evidence: CNY 5.3bnCNY 7.2bn. Growth evidence: CAGR 10.5%FCF. The management and accounting score remains deliberately conservative until dividends, buybacks, incentive dilution, related-party items, abnormal gains, and audit evidence are checked item by item.

Financial Audit

The valuation uses 2025, 2024, 2023, 2022, 2021; quote currency is CNY, valuation currency is CNY, and the risk-free-rate input is the CNY 10-year sovereign yield reference. ROIC is used only when the structured invested-capital baseline supports it.

Latest-year financials (2025): revenue CNY 22.4bn, net profit CNY 3.2bn, OCF CNY 6.0bn, capex CNY 2.1bn, FCF CNY 3.9bn, ROE 15.0%, ROIC 12.4%, FCF/Revenue 17.4%, and FCF/Net Income 1.20.

Latest balance sheet (2025): cash and equivalents CNY 5.3bn, current financial assets CNY 0.2bn, non-current financial assets CNY 1.2bn, total debt CNY 7.2bn, and net cash/debt -CNY 1.9bn. If goodwill, receivables, inventory, financial-asset marks, or off-balance-sheet obligations change materially, the fair-value bridge must be rechecked before the signal can improve.

Valuation

The model uses normalized FCF as the main anchor, then adjusts for cash, financial assets, debt, dilution, and other senior claims in common-equity order. The current price/base FV ratio is 1.38, so the base case does not satisfy the 2x discipline.

Conservative case: CNY 3.62 per share, price/FV 2.39, weight 30%.
Base case: CNY 6.30 per share, price/FV 1.38, weight 50%.
Optimistic case: CNY 8.14 per share, price/FV 1.07, weight 20%.

The balance-sheet bridge contributes cash CNY 4.8bn, current financial assets CNY 0.1bn, non-current financial assets CNY 0.4bn, debt and senior claims -CNY 7.2bn, and total adjustment -CNY 1.9bn. Dividends and buybacks are cross-checks for capital allocation and are not double-counted in FV.

Buy And Tracking Discipline

Current action: keep the stock on the stated signal and do not upgrade without a wider margin of safety. A BUY case requires price/base FV below 0.70, quality score of at least 75, and stronger evidence that the market is mispricing a still-healthy business. A 2x case requires price/base FV at or below 0.50 or new primary evidence that materially raises base fair value.

Tracking priorities are revenue trend, FCF/Net Income, OCF/Net Income, ROIC where reliable, net cash/debt, dividends, buybacks, incentive dilution, related-party disclosures, segment economics, and governance/accounting evidence.

Risks To Recheck

The key risks are repeatable FCF, balance-sheet bridge reliability, accounting and governance evidence, and shareholder-return quality. FCF that fails to repeat would lower the base multiple and the BUY threshold. Larger debt, weaker liquidity, or financial-asset impairment would reduce conservative FV. Harmful dilution, weak buyback discipline, related-party issues, or abnormal gains would reduce the management/accounting score.

Revaluation triggers are the same as in the Chinese report: two reporting periods with FCF/Net Income below 0.60; a visible increase in net debt or a material financial-asset impairment; or dividends, buybacks, incentives, or dilution that reduce ordinary-shareholder value. Any of these would require a lower quality score, lower fair value, or a weaker final signal.

Sources

The evidence set is unchanged from the Chinese report and covers market price, market value, share count, five-year financial baseline, official annual/interim filings, dividends, buybacks, governance, related-party transactions, incentives, risk disclosures, the risk-free-rate input, and currency alignment. Source URLs: https://quote.eastmoney.com/; https://www.cninfo.com.cn/; https://yield.chinabond.com.cn/cbweb-mn/yield_main?locale=zh_CN; https://quote.eastmoney.com/.

Research note: This memo is for personal research only and is not personalized investment advice.